CK0801 for Treatment of Aplastic Anemia
Latest Information Update: 05 May 2026
At a glance
- Drugs CK 0801 (Primary)
- Indications Aplastic anaemia
- Focus Therapeutic Use
- Sponsors Cellenkos
Most Recent Events
- 27 Apr 2026 According to Cellenkos media release, company announced the receipt of U.S. Food and Drug Administration (FDA) clearance to initiate CK0801 Phase 2 clinical trial, for the treatment of aplastic anemia.
- 03 Apr 2026 New trial record